@article{article, title  = {{Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2020}},

 month = {{12}},

 author = {{Powles T and van der Heijden MS and Castellano D and Galsky MD and Loriot Y and Petrylak DP and Ogawa O and Park SH and Lee J-L and De Giorgi U and Bögemann M et al}},

 doi = {{10.1016/s1470-2045(20)30541-6}},

 volume = {{21}},

 journal = {{The Lancet Oncology}},

 issue = {{12}},

 pages = {{1574-1588}},

 note = {{Accessed on 2024/12/22}}}